Unicycive Therapeutics (UNCY) Operating Expenses (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Operating Expenses came in at $8.4 million in Q1 2026, up 5.61% YoY from $8.0 million in Q1 2025, and up 16.79% on a QoQ basis from $7.2 million in Q4 2025.
Unicycive Therapeutics (UNCY) Operating Expenses (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of Operating Expenses data on file, last reported at $8.4 million in Q1 2026.
- Quarterly Operating Expenses rose 5.61% year-over-year to $8.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.0 million (down 3.03% YoY) and the FY2025 annual result came in at $29.5 million, down 8.1% from the prior year.
- Operating Expenses rose to $8.4 million in Q1 2026, from $7.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $9.3 million in Q4 2024 to a low of $3.5 million in Q1 2022.
- A 5-year average of $6.5 million and a median of $6.5 million in 2022 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses soared 383.86% — and 2025, when it dropped 22.0%.
- Tracing UNCY's Operating Expenses over 5 years: stood at $5.3 million in 2022, then grew by 18.55% to $6.3 million in 2023, then soared by 46.7% to $9.3 million in 2024, then retreated by 22.0% to $7.2 million in 2025, then rose by 16.79% to $8.4 million in 2026.
- The last three Operating Expenses figures came in at $8.4 million (Q1 2026), $7.2 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | 10.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.14 Mn |
| Mar 31, 2026 | 8.44 Mn |
| Dec 31, 2025 | 7.22 Mn |
| Sep 30, 2025 | 7.34 Mn |
| Jun 30, 2025 | 6.96 Mn |
| Mar 31, 2025 | 7.99 Mn |
| Dec 31, 2024 | 9.26 Mn |
| Sep 30, 2024 | 6.25 Mn |
| Jun 30, 2024 | 7.40 Mn |
| Mar 31, 2024 | 9.20 Mn |
| Dec 31, 2023 | 6.31 Mn |
| Sep 30, 2023 | 5.94 Mn |
| Jun 30, 2023 | 4.32 Mn |
| Mar 31, 2023 | 4.88 Mn |
| Dec 31, 2022 | 5.33 Mn |
| Sep 30, 2022 | 6.51 Mn |
| Jun 30, 2022 | 3.64 Mn |
| Mar 31, 2022 | 3.54 Mn |
| Dec 31, 2021 | 2.75 Mn |
| Sep 30, 2021 | 4.72 Mn |